LKT Laboratories, Inc.

DT-2216

Phone: 888-558-5227
651-644-8424
Fax: 888-558-7329
Email: getinfo@lktlabs.com
Web: lktlabs.com

Product Information

Product ID D760022
CAS No. 2365172-42-3
Chemical Name

Synonym DT2216

Formula $C_{77}H_{96}ClF_3N_{10}O_{10}S_4$
Formula Wt. 1542.36
Melting Point
Purity ≥98%
Solubility



Bulk quanitites available upon request

Product ID	Size
D760022	1 mg
D760022	5 mg
D760022	10 mg

Store Temp -20˚C
Ship Temp Ambient
Description DT-2216 is a proteolysis targeting chimera degrader which specifically targets Bcl-xL.

References

Negi A, Voisin-Chiret A. Strategies to reduce the on-target platelet toxicity of Bcl-xl inhibitors: PROTACs, SNIPERs, and prodrug-based approaches. Chembiochem. 2022 Jun 20;23(12):e202100689. PMID: 35263486

Shebl B, Ng D, Lalazar G, et al. Targeting BCL-XL in fibromellar hepatocellular carcinoma. JCI Insight. 2022 Sep 8;7(17): e161820. PMID: 36073545

Khan S, Wiegand J, Zhang P, et al. BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers. J Hematol Oncol. 2022 Mar 9;15(1):23. PMID: 35260176

Thummuri D, Khan S, Underwood P, et al. Overcoming gemcitabine resistance in pancreatic cancer using the BCL-XL-specific degrader DT2216. Mol Cancer Ther. 2022 Jan;21(1):184-192. PMID: 34667112